Medicare to Cover CAR -T-Cell Therapy Nationwide
August 9, 2019
In an August 7 decision memo, the Centers for Medicare and Medicaid Services announced that Medicare will start covering nationwide CAR T-cell therapy for patients with certain cancers.
“President Trump is committed to strengthening the Medicare program by ensuring that beneficiaries have access to new and potentially lifesaving treatments. As the first type of FDA-approved gene therapy, CAR T-cell therapies are an important scientific advancement in this promising new area of medicine and provide treatment options for some patients who had nowhere else to turn,” CMS Administrator Seema Verma said in a release.
Additional Read:
Medicare will Cover Pioneering Cancer Treatment Nationwide – The Washington Post
Recent News
- Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)
- Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen
- Growing collaboration with New York Kidney & Hypertension Medicine
- CancerVax Scientists Featured on Cytiva’s “Discovery Matters” Podcast Discussing Universal Cancer Vaccine Platform
- Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting
- BD to Initiate Real-World Patient Data Registry for the Rotarex™ Atherectomy System in Treatment of Peripheral Artery Disease
